Heart failure management at home: a non-randomised prospective case-controlled trial (HeMan at Home).
Health Care Economics and Organizations
Heart Failure
Outcome Assessment, Health Care
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
07 Dec 2023
07 Dec 2023
Historique:
received:
31
05
2023
accepted:
05
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
8
12
2023
Statut:
epublish
Résumé
Heart failure (HF) is a growing clinical and economic burden for patients and health systems. The COVID-19 pandemic has led to avoidance and delay in care, resulting in increased morbidity and mortality among many patients with HF. The increasing burden of HF during the COVID-19 pandemic led us to evaluate the quality and safety of the Hospital at Home (HAH) for patients presenting to their community providers or emergency department (ED) with symptoms of acute on chronic HF (CHF) requiring admission. A non-randomised prospective case-controlled of patients enrolled in the HAH versus admission to the hospital (usual care, UC). Primary outcomes included length of stay (LOS), adverse events, discharge disposition and patient satisfaction. Secondary outcomes included 30-day readmission rates, 30-day ED usage and ED dwell time. Sixty patients met inclusion/exclusion criteria and were included in the study. Of the 60 patients, 40 were in the HAH and 20 were in the UC group. Primary outcomes demonstrated that HAH patients had slightly longer LOS (6.3 days vs 4.7 days); however, fewer adverse events (12.5% vs 35%) compared with the UC group. Those enrolled in the HAH programme were less likely to be discharged with postacute services (skilled nursing facility or home health). HAH was associated with increased patient satisfaction compared with Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) score in North Carolina. Secondary outcomes of 30-day readmission and ED usage were similar between HAH and UC. The HAH pilot programme was shown to be a safe and effective alternative to hospitalisation for the appropriately selected patient presenting with acute on CHF.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Heart failure (HF) is a growing clinical and economic burden for patients and health systems. The COVID-19 pandemic has led to avoidance and delay in care, resulting in increased morbidity and mortality among many patients with HF. The increasing burden of HF during the COVID-19 pandemic led us to evaluate the quality and safety of the Hospital at Home (HAH) for patients presenting to their community providers or emergency department (ED) with symptoms of acute on chronic HF (CHF) requiring admission.
DESIGN/OUTCOMES
UNASSIGNED
A non-randomised prospective case-controlled of patients enrolled in the HAH versus admission to the hospital (usual care, UC). Primary outcomes included length of stay (LOS), adverse events, discharge disposition and patient satisfaction. Secondary outcomes included 30-day readmission rates, 30-day ED usage and ED dwell time.
RESULTS
RESULTS
Sixty patients met inclusion/exclusion criteria and were included in the study. Of the 60 patients, 40 were in the HAH and 20 were in the UC group. Primary outcomes demonstrated that HAH patients had slightly longer LOS (6.3 days vs 4.7 days); however, fewer adverse events (12.5% vs 35%) compared with the UC group. Those enrolled in the HAH programme were less likely to be discharged with postacute services (skilled nursing facility or home health). HAH was associated with increased patient satisfaction compared with Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) score in North Carolina. Secondary outcomes of 30-day readmission and ED usage were similar between HAH and UC.
CONCLUSIONS
CONCLUSIONS
The HAH pilot programme was shown to be a safe and effective alternative to hospitalisation for the appropriately selected patient presenting with acute on CHF.
Identifiants
pubmed: 38065589
pii: openhrt-2023-002371
doi: 10.1136/openhrt-2023-002371
pmc: PMC10711907
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Emerg Med J. 2012 Dec;29(12):e5
pubmed: 22158534
N Engl J Med. 2010 Oct 7;363(15):1419-28
pubmed: 20925544
Acad Emerg Med. 2005 Jun;12(6):514-21
pubmed: 15930402
J Am Geriatr Soc. 1998 May;46(5):605-9
pubmed: 9588374
JAMA. 2003 Nov 19;290(19):2581-7
pubmed: 14625335
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257
pubmed: 32915166
J Card Fail. 2003 Feb;9(1):13-25
pubmed: 12612868
Ann Intern Med. 2012 Jun 5;156(11):767-75, W-261, W-262
pubmed: 22665814
World J Cardiol. 2015 Dec 26;7(12):902-11
pubmed: 26730296
Circ Heart Fail. 2016 Aug;9(8):
pubmed: 27514749
Card Fail Rev. 2017 Apr;3(1):7-11
pubmed: 28785469
Pharmacoeconomics. 2020 Nov;38(11):1219-1236
pubmed: 32812149
Am Heart J. 2008 Oct;156(4):662-73
pubmed: 18926148
J Am Coll Cardiol. 2013 Mar 26;61(12):1259-67
pubmed: 23500328
MMWR Morb Mortal Wkly Rep. 2020 Jun 26;69(25):795-800
pubmed: 32584802
J Am Coll Cardiol. 2010 Mar 2;55(9):872-8
pubmed: 20185037
Med J Aust. 2012 Nov 5;197(9):512-9
pubmed: 23121588
J Am Geriatr Soc. 1999 Jun;47(6):697-702
pubmed: 10366169
Cochrane Database Syst Rev. 2016 Sep 01;9:CD007491
pubmed: 27583824
Health Aff (Millwood). 2012 Jun;31(6):1237-43
pubmed: 22665835
J Am Coll Cardiol. 2008 Jul 29;52(5):347-56
pubmed: 18652942
Eur J Heart Fail. 2012 Jun;14(6):605-12
pubmed: 22535795
Acad Emerg Med. 2013 Jan;20(1):17-26
pubmed: 23570474
Eur J Heart Fail. 2009 Dec;11(12):1208-13
pubmed: 19875400
J Gen Intern Med. 2021 Jul;36(7):1965-1973
pubmed: 33479931
Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32
pubmed: 20123668
J Card Fail. 2004 Dec;10(6):460-6
pubmed: 15599835
Acta Med Port. 2017 Dec 29;30(12):835-839
pubmed: 29364795
Med J Aust. 2010 Nov 15;193(10):598-601
pubmed: 21077817
J Am Geriatr Soc. 2008 Mar;56(3):493-500
pubmed: 18179503
Heart. 2014 Jan;100(2):115-25
pubmed: 24179162
Arch Gerontol Geriatr Suppl. 2004;(9):431-6
pubmed: 15207444
Prog Cardiovasc Dis. 2016 Jan-Feb;58(4):379-85
pubmed: 26432556
Int J Cardiol. 2013 Oct 3;168(3):2120-6
pubmed: 23395457
Int J Cardiol. 2014 Feb 15;171(3):368-76
pubmed: 24398230
Can J Cardiol. 2018 Feb;34(2):168-179
pubmed: 29287944
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Am J Manag Care. 2009 Jan;15(1):49-56
pubmed: 19146364
J Health Serv Res Policy. 2005 Jul;10(3):158-66
pubmed: 16053592
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Eur J Heart Fail. 2020 Jun;22(6):978-984
pubmed: 32478951
CMAJ. 2009 Jan 20;180(2):175-82
pubmed: 19153394
J Cardiol. 2014 Dec;64(6):441-9
pubmed: 24794758
Ann Intern Med. 2020 Jan 21;172(2):77-85
pubmed: 31842232
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):965-967
pubmed: 32604016
Ann Intern Med. 2005 Dec 6;143(11):798-808
pubmed: 16330791